A team led by Japanese biotech venture AnGes, Inc. will ready production capacity for 1 million doses of coronavirus vaccines by March, a fivefold increase from the original plan, in order to ensure swift access to the domestic population.As top pharmaceutical companies in the U.S. and elsewhere rush to set up facilities capable of producing billions of doses of vaccines, there is no guarantee that Japan can import them. The government hopes to
